TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04849494

Intervention type: OTHER
Intervention: ATS-DLD-78-C and ISAAC questionnaires
Description: Early, natal and postnatal period data were recorded from the hospital database system and patient file. The morbidities observed during the follow-up of the newborns, the duration of hospitalization, needed of oxygen, surfactant administration, positive pressure ventilation requirement, and need for mechanical ventilation support and duration were noted from patient file records. Anthropometric measurements of all patients were taken. Demographic information, socioeconomic level, mother/father education level, mother's smoking status and medical history were questioned, and physical examinations of the patients were performed. were performed for screening respiratory diseases. After the physical examination, the validated Turkish forms of ATS-DLD-78-C and ISAAC questionnaires were filled in face-to-face by the research doctor who did not know the patients' medical history

Intervention type: OTHER
Intervention: ATS-DLD-78-C and ISAAC questionnaires
Description: Early, natal and postnatal period data were recorded from the hospital database system and patient file. The morbidities observed during the follow-up of the newborns, the duration of hospitalization, needed of oxygen, surfactant administration, positive pressure ventilation requirement, and need for mechanical ventilation support and duration were noted from patient file records. Anthropometric measurements of all patients were taken. Demographic information, socioeconomic level, mother/father education level, mother's smoking status and medical history were questioned, and physical examinations of the patients were performed. were performed for screening respiratory diseases. After the physical examination, the validated Turkish forms of ATS-DLD-78-C and ISAAC questionnaires were filled in face-to-face by the research doctor who did not know the patients' medical history

Intervention type: OTHER
Intervention: ATS-DLD-78-C and ISAAC questionnaires
Description: Early, natal and postnatal period data were recorded from the hospital database system and patient file. The morbidities observed during the follow-up of the newborns, the duration of hospitalization, needed of oxygen, surfactant administration, positive pressure ventilation requirement, and need for mechanical ventilation support and duration were noted from patient file records. Anthropometric measurements of all patients were taken. Demographic information, socioeconomic level, mother/father education level, mother's smoking status and medical history were questioned, and physical examinations of the patients were performed. were performed for screening respiratory diseases. After the physical examination, the validated Turkish forms of ATS-DLD-78-C and ISAAC questionnaires were filled in face-to-face by the research doctor who did not know the patients' medical history
Study: NCT00614601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute(R)-Pancreatic Cancer Vaccine
Description: 100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute(R)-Pancreatic Cancer Vaccine
Description: 100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
Study: NCT04695743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Cognitive Stimulation Therapy
Description: Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
Study: NCT03403218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case group
Description: assessment of quality on posture, transfers and displacement
Study: NCT04579822

Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: quadrivalent influenza vaccination in the flu seasons

Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: quadrivalent influenza vaccination in the flu seasons
Study: NCT02796625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Painful Stimuli
Description: warm or painful heat administration
Study: NCT00208780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Study: NCT03034538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: 200mg
Study: NCT04275089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reia Vaginal Pessary
Description: Reia Vaginal Pessary
Study: NCT00913237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
Study: NCT00933855

Intervention type: BEHAVIORAL
Intervention: Questionnaires and training workshop
Description: We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment
Study: NCT03902925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection
Description: Lidocaine 2% jelly applied to conjunctival fornices for 5 minutes then injection of 2-4 ml of ropivacaine 10% in the sub-tenon space with a blunt cannula through a temporal inferior incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peribulbar injection
Description: Peribulbar injection of 4-6 ml of ropivacaine 10%
Study: NCT02717403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete a self response electronic questionnaire at baseline, and at three and six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete a self response electronic questionnaire at baseline, and at three and six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook
Description: Participant accesses Facebook page regarding rheumatoid arthritis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook
Description: Participant accesses Facebook page regarding rheumatoid arthritis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Website
Description: Participant accesses Educational Website on the internet about rheumatoid arthritis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Website
Description: Participant accesses Educational Website on the internet about rheumatoid arthritis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Website
Description: Participant accesses Educational Website on the internet about rheumatoid arthritis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Interview
Description: Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
Study: NCT00636077

Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux HD-C4 Big
Description: Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.

Intervention type: DEVICE
Group type: OTHER
Intervention: HD-C4 Small
Description: Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optiflux 160NR
Description: Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optiflux 200NR
Description: Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
Study: NCT02350777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion
Description: For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10\^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion
Description: For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10\^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Cell Selection System
Study: NCT06592976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain Oral Probiotic (CDS22-formula)
Description: All patients received the probiotic product CDS22-formula (also known under the tradenames Visbiome, De Simo-ne, Vivomixx) as acid-resistant oral capsules (twice daily for 2 months), containing 1.12 x 10\^11 live bacteria per capsule.
Study: NCT02350777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Cell Selection System
Study: NCT00470340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, gemcitabine, cisplatin, lipiodol
Description: Oxaliplatin, gemcitabine, cisplatin, lipiodol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, gemcitabine, cisplatin, lipiodol
Description: Oxaliplatin, gemcitabine, cisplatin, lipiodol
Study: NCT03018951

Intervention type: OTHER
Intervention: Tool Development meeting
Description: Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.

Intervention type: OTHER
Intervention: Pilot Test 1 assessment session
Description: Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.

Intervention type: OTHER
Intervention: Pilot Test 2 assessment session
Description: Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
Study: NCT04603638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic
Description: 100 ml
Study: NCT04637178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training sessions twice a week for ten weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance training (habitual)
Description: Endurance training for ten weeks (habitual routines)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training (habitual)
Description: Endurance training for ten weeks (habitual routines)
Study: NCT03785171

Intervention type: PROCEDURE
Intervention: surgical revascularization
Description: Indirect revascularization procedure
Study: NCT03038438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abre venous self-expanding stent system
Description: venous stent
Study: NCT00355199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab-HDS
Description: Rituximab-HDS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-CHOP
Description: Rituximab-CHOP
Study: NCT02952807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: vaginal Misoprostol Plus Foley Catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: vaginal Misoprostol Plus Foley Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Study: NCT02183051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 3.75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 1.875 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Study: NCT06283368

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Bilaterally Total
Description: Thyroidectomy, Bilaterally Total

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Bilaterally Total
Description: Thyroidectomy, Bilaterally Total

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Unilaterally Total
Description: Thyroidectomy, Unilaterally Total

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Unilaterally Total
Description: Thyroidectomy, Unilaterally Total

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Complementary
Description: Thyroidectomy, Complementary

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Complementary
Description: Thyroidectomy, Complementary

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Near Total
Description: Thyroidectomy, Near Total

Intervention type: PROCEDURE
Intervention: Thyroidectomy, Near Total
Description: Thyroidectomy, Near Total
Study: NCT00653445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg
Study: NCT05823831

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire
Description: Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire
Description: Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Infant Sleep Questionnaire (BISQ) questionnaire
Description: A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Infant Sleep Questionnaire (BISQ) questionnaire
Description: A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire
Description: A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire
Description: A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Symptom Inventory (BSI) questionnaire
Description: A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Symptom Inventory (BSI) questionnaire
Description: A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
Study: NCT01944371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
Study: NCT00069108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU
Description: As prescribed, in 2 week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: As prescribed, in 2 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: As prescribed, in 3 week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: As prescribed, in 2 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-15 of each 3 week cycle
Study: NCT04413773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual + Video
Description: Additionally to treatment as usual a video is shown to participant about procedures on the ward before, during and after surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Explanation of standard procedures before, during and after surgery by nurse
Study: NCT01453803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harvesting and Implantation of Adipose-Derived Stem Cells
Description: The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
Study: NCT02873091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent epidural bolus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent epidural bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Study: NCT03773315

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UMH extract
Description: Schisandra chinensis extract 500 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch placebo 500 mg/day for 12 weeks
Study: NCT00969527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin + Viusid
Description: 50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of Placebo (orally administered) twice a day, for 12 weeks.